Hydroquinone and its analogues in dermatology - A risk-benefit viewpoint

Journal of Cosmetic Dermatology

Volumn 5, Issue 3, 2006, Pages 196-203

  O'Donoghue, J L ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NONE

Author keywords

Arbutin; Hydroquinone; Risk benefit; Skin lightening; Toxicity

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; ANTIMUTAGENIC AGENT; ARBUTIN; ARCTOSTAPHYLOS UVA URSI EXTRACT; BENZENE; BENZOQUINONE; CARCINOGEN; COSMETIC; DERMATOLOGICAL AGENT; GLUTATHIONE; HYDROQUINONE; HYDROQUINONE DERIVATIVE; PHENOL DERIVATIVE; PLANT EXTRACT; RESORCINOL;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER SCREENING; CARCINOGENICITY; CHRONIC TOXICITY; COSMETIC INDUSTRY; DERMATOLOGY; DEVELOPMENTAL DISORDER; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; EUROPEAN UNION; FOOD COMPOSITION; FOOD INTAKE; HUMAN; HYPERPIGMENTATION; INCIDENCE; INTERMETHOD COMPARISON; LEUKODERMA; LOTION; NEPHROTOXICITY; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; OCHRONOSIS; PIGMENT DISORDER; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANCER; SKIN IRRITATION; SKIN PIGMENTATION; SKIN TOXICITY; URINARY EXCRETION; VITILIGO; WORK ENVIRONMENT;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; COSMETICS; HUMANS; HYDROQUINONES;

EID: 33748184861     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2006.00253.x     Document Type: Review

References (53)

1. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology -a potential health risk. J Cosmet Dermatol 2005; 4: 55-9.
2. Kooyers TJ, Westerhof W. Toxicology and health risks of hydroquinone in skin lightening formulations. J Eur Acad Dermatol Venereology; in press; doi: 10.1111/j.1468-3083.2005.01218.x.
3. Kooyers TJ, Westerhof W. [Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula] Ned Tijdschr Geneeskd 2004; 148: 768-71.
4. Cosmetic Toiletries and Fragrances Association. Final report on the safety assessment of hydroquinone and pyrocatechol. J Am Coll Toxicol 1986; 5: 123-65.
5. Cosmetic Toiletries and Fragrances Association. Addendum to the final report on the safety assessment of hydroquinone. J Am Coll Toxicol 1994; 13: 167-230.
6. International Agency for Research on Cancer. Hydroquinone. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Re-Evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide, Vol. 71. Part 2;PGeneva: World Health Organization; 1999: pp. 691-719.
7. DeCaprio AP. The toxicology of hydroquinone -relevance to occupational and environmental exposure. Crit Rev Toxicol 1998; 29: 283-330.
8. Gingell R, O'Donoghue JL, Staab RJ et al. Phenol and phenolics. In: E Bingham, B Cohrssen, CH Powell, eds. Patty's Toxicology, 5th edn, Vol. 4. New York: John WileyP& Sons; 2001: pp. 383-551.
9. International Programme on Chemical Safety (1994). Environmental Health Criteria 157: Hydroquinone. Geneva: WorldHealth Organization; 1994.
10. UNEP Publications. SIDS Initial Assessment Profile: Hydroquinone [WWW Hocument]. URL http://www.chem.unep.ch/irptc/sids/oecdsids/123319.pdf
11. Whysner J, Verna L, English JC, Williams GM. Analysis of studies related to tumorigenicity induced by hydroquinone. Reg Toxicol Pharmacol 1995; 21: 158-76.
12. Arndt KA, Fitzpatrick TB. Topical use of hydroquinone as a depigmenting agent. J Am Med Assoc 1965; 194: 965-7.
13. Burke PA, Maibach HI. Exogenous ochronosis: An overview. J Dermatolog Treat 1997; 8: 21-6.
14. Twenty-fourth Commission Directive 2000/6/EC. Official J Eur Commun 2000; L56: 42-6.
15. Commission Directive 2003/83/EC. Official J Eur Union 2003; L238: 23-7.
16. Siegers CP, Siegers JP, Pentz R, Bodinet C, Freudenstein J. Metabolism of arbutin from Uvae ursi -extracts in humans. Pharm Pharmacol Lett 1997; 7: 90-2.
17. Cosmetic, Toiletries and Fragrances Association of South Africa. (2006) The bearberry/arbutin project [WWW document] URL http://www.ctfa.co.za/ pebble.asp?relid=18331=298
18. Levin CY, Maibach H. Exogenous ochronosis; an update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213-7.
19. Deisinger PJ, Hill TS, English JC. Human exposure to naturally occurring hydroquinone. J Toxicol Environ Health 1996; 47: 101-16.
20. McDonald TA, Holland NT, Skibola C et al. Hypothesis; phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia 2001; 15: 10-20.
21. Wester RC, Melendres J, Hui X et al. Human in vivo and in vitro hydroquinone bioavailability, metabolism and disposition. J Toxicol Environ Health, Part A 1998; 54: 301-17.
22. English JC, Deisinger PJ. Metabolism and disposition of hydroquinone in Fischer 344 rats after oral and dermal administration. Fd Chem Toxicol 2005; 43: 483-93.
23. Corley RA, English JC, Hill TS et al. Development of a physiologically based pharmacokinetic model for hydroquinone. Toxicol Appl Pharmacol 2000; 165: 163-74.
24. Poet TS, Wu H, English JC, Corley RA. Metabolic rate constants for hydroquinone in F344 rat and human liver isolated hepatocytes: application to a PBPK model. Toxicol Sci 2004; 82: 9-25.
25. Sterner JH, Oglesby FL, Anderson B. Quinone vapors and their harmful effects. I. corneal and conjuctival injury. J Ind Hyg Toxicol 1947; 26: 60-73.
26. Carlson AJ, Brewer NR. Toxicity studies on hydroquinone. Proc Soc Exp Biol Med 1953; 84: 684-8.
27. Pifer JW, Hearne FT, Swanson FA, O'Donoghue JL. Mortality study of employees engaged in the manufacture and use of hydroquinone. Int Arch Occup Environ Health 1995; 67: 267-80.
28. Pifer JW, Hearne FT, Friedlander BR, McDonough JR. Mortality study of men employed at a large chemical plant, 1972 through 1982. J Occup Med 1986; 28: 438-44.
29. Friedlander BR, Hearne FT, Newmann BJ. Mortality, cancer incidence, and sickness-absence in photographic processors: An epidemiologic study. J Occup Med 1982; 24: 605-13.
30. Krasavage WJ, Blacker AM, English JC, Murphy SJ. Hydroquinone: A developmental toxicity study in rats. Fund Appl Toxicol 1992; 18: 370-5.
31. Murphy SJ, Schroeder RE, Blacker AM et al. A study of developmental toxicity of hydroquinone (HQ) in the rabbit. Fund Appl Toxicol 1992; 19: 214-21.
32. Blacker AM, Schroeder RE, English JC et al. A two-generation reproduction study with hydroquinone in rats. Fund Appl Toxicol 1993; 21: 420-4.
33. Topping D, Bernard L, Blacker A et al. Subchronic functional observational battery (FOB) and neuropathology studies on hydroquinone. Toxicologist 1991; 11: 167.
34. 1 mice. NIH Publication No. 90-2821, Research Triangle Park, NC: NIH; 1989.
35. Hard GC, Whysner J, English JC et al. Relationship of hydroquinone-associated rat renal tumors with spontaneous CPN. Toxicol Path 1997; 25: 132-43.
36. Shibata M-A, Hirose M, Tanaka H et al. Induction of renal cell tumors in rats and mice, and enhancement of hepatocellular tumor development in mice after long-term hydroquinone treatment. Jap J Can Res 1991; 82: 1211-9.
37. English JC, Perry LG, Vlaovic M et al. Measurement of cell proliferation in the kidneys of Fischer 344 and Sprague-Dawley rats after gavage administration of hydroquinone. Fund Appl Toxicol 1994; 23: 397-406.
38. 32 P-postlabeling in the kidney of male and female Fischer 344 rats after multiple gavage doses of hydroquinone. Fund Appl Toxicol 1994; 23: 391-6.
39. Cosmetic, Toiletry and Fragrance Association. Thirteen week subchronic dermal toxicity study of hydroquinone. CTFA Code 2-23b-8, Washington, DC: CTFA; 1981.
40. David RM, English JC, Totman LC et al. Lack of nephrotoxicity and renal cell proliferation following subchronic dermal application of hydroquinone cream. Fd Chem Toxicol 1998; 36: 609-16.
41. Van Duuren B, Goldschmidt B. Cocarcinogenic and tumor-promoting agents in tobacco carcinogenesis. J Natl Cancer Inst 1976; 56: 1237-42.
42. Boutwell RK, Bosch DK. The tumor-promoting action of phenol and related compounds for mouse skin. Cancer Res 1959; 19: 413-24.
43. International Agency for Research on Cancer. (1987) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Benzene Supplement 7 [WWW document] URL http://www-cie.iarc.fr/htdocs/monographs/suppl7/ benzene.html
44. Snyder R, Hedli CC. An overview of benzene metabolism. Environ Hlth Perspec 1996; 104: 1165-71.
45. National Toxicology Program. Toxicology and carcinogenesis studies of benzene in F-344/N rats and B6C3F 1 mice. NIH Publication No. 86-2545, Research Triangle Park, NC: NIH; 1986.
46. O'Donoghue JL, Barber ED, Hill T, Aebi J, Fiorica L. Hydroquinone: genotoxicity and prevention of genotoxicity following ingestion. Fd Chem Toxicol 1999; 37: 931-6.
47. Williams GM, Iatropoulos MJ, Jeffrey AM. Anticarcinogenicity of monocyclic phenolic compounds. Eur J Cancer Prev 2002; 11: S101-7.
48. Hagiwara A, Kokubo Y, Takesada Y et al. Inhibitory effects of phenolic compounds on development of naturally occurring preneoplastic hepatocytic foci in long-term feeding studies using male F344 rats. Teratogen, Carcinogen Mutagen 1996; 16: 317-25.
49. Takizawa T, Imai T, Onose J-I et al. Enhancement of hepatocarcinogenesis by kojic acid in rat two-stage models after initiation with N-bis (2-hydroxypropyl) nitrosamine or N-diethylnitrosamine. Toxicol Sci 2004; 81: 43-9.
50. Eastmond DA, Smith MT, Irons RD. An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. Toxicol Appl Pharmacol 1987; 91: 85-95.
51. Barale R, Marrazzini A, Betti C et al. Genotoxicity of two metabolites of benzene: Phenol and hydroquinone show strong synergistic effects in vivo. Mutat Res 1990; 244: 15-20.
52. Brugnone F, Perbellini L, Faccini GB et al. Benzene in the blood and breath of normal people and occupationally exposed workers. Am J Indust Med 1989; 16: 385-99.
53. Brugnone F, Perbellini L, Maranelli G et al. Reference values for blood benzene in the occupationally unexposed general population. Int Arch Occup Environ Hlth 1992; 64: 179-84.